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Introduction
RUNX1 (also called AML1) is a member of the RUNX transcription factor family and plays an essential role in the development of normal hematopoiesis (1, 2). RUNX1 forms a core-binding factor (CBF) complex with its cofactor, CBFB. RUNX1 and CBFB are the most frequent targets of chromosomal translocations in acute myeloid leukemia (AML), generating the leukemogenic fusion proteins AML1-ETO and CBFB-MYH11. In these CBF leukemias, the dominant inhibition of RUNX1 function by these fusion proteins has been considered a critical pathway for leukemia development (3) . In MLL fusion leukemia, RUNX1 expression is downregulated through degradation by MLL fusion proteins (ref. 4 and G. Huang, unpublished observations). Furthermore, inactivating RUNX1 mutations have been frequently found in a variety of myeloid neoplasms, including myelodysplastic syndrome (MDS) and cytogenetically normal AML (5) (6) (7) (8) . Therefore, RUNX1 has been regarded as a beneficial tumor suppressor for myeloid leukemogenesis. The tumor suppressor activity of RUNX1 has also been demonstrated in several mouse AML models. Runx1-deficient cells showed increased susceptibility to AML development in collaboration with MLL-ENL, NRAS G12S , and EVI5 (9) (10) (11) .
However, human genetic evidence also raises the possibility that RUNX1 activity is required for optimal growth of AML cells. RUNX1 mutation is usually heterozygous, and complete loss of RUNX1 is rarely seen in human AMLs. In particular, no RUNX1 mutation was found in AMLs with leukemogenic fusion proteins, such as CBF and MLL fusion leukemias (7, 8, 12) . Experimentally, it was shown that Cbfb-Myh11 knockin mice developed leukemia partly through RUNX1 repression-independent activities, and a mutant CBFB-MYH11 lacking the RUNX1 binding domain induced leukemia quickly despite its inefficient suppression of RUNX1 function (13, 14) .
We have developed an experimental system to model myeloid leukemogenesis using primary human cord blood (CB) cells (15, 16) . The CBF fusion proteins AML1-ETO and CBFB-MYH11 promote self-renewal and long-term proliferation of human CB CD34 + cells in vitro (17) (18) (19) . The MLL fusion protein MLL-AF9 immortalizes CB cells in vitro and produces human leukemia in immunodeficient mice (20) . These engineered pre-leukemic and leukemic cells recapitulate many features of the clinical diseases and have been useful in testing different therapeutic strategies (21) (22) (23) (24) (25) .
Using these human cell-based models, we identified a contextspecific, dual role for RUNX1 in human myeloid neoplasms. Consistent with the general assumption, RUNX1 induces myeloid differentiation in normal CB cells, thereby working as a tumor suppressor. Unexpectedly, we also found that RUNX1 plays a critical role in the growth and survival of human AML cells. We used a mouse model of AML, which demonstrated that the combined deletion of Runx1/Cbfb diminishes the leukemogenic activity of murine MLL-AF9 cells. Our study uncovers a prosurvival role for RUNX1 in myeloid leukemia and identifies RUNX1 as a potential therapeutic target beyond CBF leukemia.
Results
RUNX1 inhibits the growth of human CB cells. We first examined the effect of forced expression of RUNX1 and its mutants in human CB CD34 + cells. R139G and D171N have a point mutation in the RUNT domain. S291fsX9 (S291fs) is a C-terminal truncation mutant lacking an activation domain. L378fsX196ΔEx7 (L378fs) is a C-terminal elongation mutant and lacks sequences of exon 7. These mutations were identified exclusively in MDS/AML patients and were shown to have a dominant-negative effect over wild-type RUNX1 (5, 26, 27) . L29S was also detected in 5% of healthy people and may not be relevant to leukemogenesis (ref. 7 and Figure 1A ). We confirmed the expression of each protein by immunoblotting in CB cells ( Figure 1B ). RUNX1 and L29S inhibited the growth of CB cells, as evidenced by the loss of GFP-expressing cells in culture. In contrast, the frequency of the cells expressing other mutants gradually increased at the late phase of culture, suggesting enhanced self-renewal of these cells ( Figure 1C ). We found that RUNX1expressing cells showed decreased CD34 (a stem cell marker) and increased CSF2RA (a marker for myeloid differentiation) expression, suggesting that RUNX1 induces myeloid differentiation of CD34 + cells. Leukemogenic RUNX1 mutants lost this activity ( Figure 1D ). In particular, S291fs-expressing cells eventually dominated the culture and grew for more than 3 months (Supplemental Discussion and Supplemental Figure 1 ; supplemental material available online with this article; doi:10.1172/JCI68557DS1). We also assessed cell cycle status and apoptosis on days 5 through 7 of culture in CB cells expressing RUNX1, D171N, S291fs, or vector. D171N decreased the frequency of CB cells in the S/G2/M phases, consistent with its transient inhibitory effect during the early phase of culture. Wild-type RUNX1 slightly increased the frequency of annexin V + apoptotic cells, which may also contribute to the growth-inhibitory effect of RUNX1 in CB cells ( Figure 1E ). Thus, RUNX1 acts as a tumor suppressor in CB cells mainly by inducing myeloid differentiation, and loss of this differentiation-inducing activity is a common feature of leukemogenic RUNX1 mutants.
Mutant RUNX1 inhibits the growth of human AML cells. Next, we transduced RUNX1 and its mutants (D171N and S291fs) into the engineered human AML cells generated by expressing AML1-ETO or MLL-AF9 in human CB cells (18) (19) (20) . Interestingly, both mutants inhibited the growth of these engineered AML cells ( Changes in frequency of GFP + cells (vector/RUNX1/mutant-expressing cells) in two independent CB cell cultures. RUNX1 and the L29S mutant inhibited the growth of CB cells, while other mutants did not. (D) CD34 and CSF2RA expression in vector/RUNX1/mutant-transduced cells on day 7 of culture. GFP + cells were gated and analyzed. The percentage of cells in each gate (CD34 + or CSF2RA + cells) is indicated. (E) CB cells were transduced with vector, RUNX1, or its mutants (D171N and S291fs) and were cultured with cytokines. Cell cycle status and apoptosis were assessed on days 5 through 7 of culture. The frequency of S/G2/M phase cells in GFP + cells (transduced cells) was first normalized to that in GFPcells (nontransduced cells) and then was normalized to that of the vector control. For apoptosis, the frequency of annexin V + cells in GFP + cells was normalized to that of the vector control. Three independent experiments were performed, and data are shown as the mean ± SEM. and C), but the growth-inhibitory effect of RUNX1 was not seen in MLL-AF9 cells ( Figure 2B ). Similar to the results seen in CB cells, the mutants did not decrease CD34 expression in AML1-ETO cells ( Figure 2C ). Instead, the mutant-expressing AML cells showed a decrease in the proportion of S/G2/M phase cells and an increase in the proportion of annexin V + cells compared with vector-transduced cells. In particular, the mutants, but not wild-type RUNX1, induced cell cycle arrest in AML1-ETO cells and apoptosis in MLL-AF9 cells ( Figure 2 , D and E). Because the mutant overexpression perturbs RUNX1-mediated gene regulation (Supplemental Figure  2 and Supplemental Discussion), these results indicate that proper RUNX1 function is necessary for efficient growth of these AML cells and could explain why no RUNX1 mutation was found in CBF and MLL fusion leukemias.
RUNX1 depletion inhibits the growth of human AML cells. RUNX1 was abundantly expressed and phosphorylated in all the engineered human AML cells, with the highest expression in AML1-ETO cells ( Figure 3 , A and B). To assess the role of endogenous RUNX1 in human cells, we knocked down RUNX1 expression in CB, in the engineered AML cells, and in myeloid cell lines using two indepen-dent RUNX1-specific shRNA lentiviruses that showed modest (sh-1) and strong (sh-2) knockdown efficiency ( Figure 3C and Supplemental Figure 3A , B). We found that the reduction of RUNX1 expression resulted in substantial growth inhibition in both CB and AML cells, but the growth-inhibitory effect was relatively weak in CB cells ( Figure 3D and Supplemental Figure 3C ). The growth of BCR-ABLdriven leukemia cells (K562) was unaffected by RUNX1 reduction (Supplemental Figure 3D ). Cell cycle and apoptosis analysis revealed a substantial decrease in the proportion of S/G2/M phase cells and an increase in the percentage of annexin V + cells in RUNX1-depleted AML1-ETO and MLL-AF9 cells ( Figure 3 , E and F). Consistent with the results of mutant overexpression, RUNX1 depletion blocked myeloid differentiation in CB and AML1-ETO cells, as evidenced by an increased expression of the stem cell marker CD34 (Supplemental Figure 3E ). Thus, RUNX1 promotes cell cycle progression and inhibits apoptosis in AML cells, thereby supporting their growth.
Reintroduction of RUNX1 reverses the negative effect of RUNX1 shRNAs. It has been shown that some shRNAs have off-target or nonspecific toxicity (28) . We therefore examined whether the reintroduction of RUNX1 could reverse the growth-inhibitory effect (D and E) Cells were transduced with vector, RUNX1, or its mutants (D171N and S291fs) and were cultured with cytokines. Cell cycle status and apoptosis were assessed on days 5 through 7 of culture. The frequency of S/G2/M phase cells in GFP + cells (transduced cells) was first normalized to that in GFPcells (nontransduced cells) and then was normalized to that of the vector control (D). For apoptosis, the frequency of annexin V + cells in GFP + cells was normalized to that of the vector control (E). Three or four independent experiments were performed, and data are shown as the mean ± SEM. of each shRNA. We cotransduced vector or RUNX1 (coexpressing GFP) with each shRNA (coexpressing venus) in MLL-AF9 cells and monitored changes in GFP/venus frequency in culture. High expression of RUNX1 in GFP + and GFP/venus double-positive (DP) populations was confirmed by immunoblotting ( Figure 4A ). In the vector-transduced cultures, the frequency of both venus + and DP cells decreased on day 11 because of the growth-inhibitory effect of RUNX1 shRNAs. In contrast, RUNX1 reintroduction in the DP cells prevented this negative effect, as evidenced by the abundant DP cells in the cultures on day 11 ( Figure 4B ). The shRNA-resistant versions of RUNX1 also reversed the negative effect of each shRNA (Supplemental Figure 4 ). Furthermore, RUNX1-5A, a nonfunctional RUNX1 mutant carrying five phos-pho-deficient mutations (29), did not reverse the negative effect of sh-2, whereas all functional RUNX1 (wild-type, RUNX1-2A, and RUNX1-4A) did ( Figure 4 , C and D, Supplemental Figure 5 , and Supplemental Discussion). Taken together, we conclude that the growth-inhibitory effect of the RUNX1 shRNAs is in fact due to RUNX1 downregulation.
Inhibiting RUNX1 function suppresses human MLL fusion leukemia. Using MLL-AF9-expressing CB cells as a model for human AML (20) , we further assessed the role for RUNX1 in the generation of AML. We cotransduced MLL-AF9 (coexpressing GFP) with a nontargeting (NT) control shRNA or RUNX1 shRNA (coexpressing venus) into CD34 + cells and cultured the cells in vitro or directly transplanted them into the NOD/SCID mice in which Figure 3B . (D) Changes in frequency of venus + cells (shRNA-transduced cells) in two independent CB, AML1-ETO, and MLL-AF9 cell cultures. (E and F) Cells were transduced with NT control or RUNX1 shRNA (sh-1 or sh-2) and were cultured with cytokines. Cell cycle status and apoptosis were assessed on days 5 through 7 of culture. For cell cycle status, the frequency of S/G2/M phase cells in venus + cells (transduced cells) was first normalized to that in venuscells (untransduced cells) and then was normalized to that of the NT control (E). For apoptosis, the frequency of annexin V + cells in venus + cells was normalized to that of the NT control (F). Four independent experiments were performed, and data are shown as the mean ± SEM. several human cytokine genes (SCF, GMCSF, and IL3) are transgenically expressed (NS-S/GM/3: NSS) (ref. 30 and Figure 5A ). In these mice, MLL-AF9-expressing CB cells produced human AML within 4 to 5 weeks ( Figure 5B ). Consistent with earlier results, RUNX1 depletion inhibited the MLL-AF9-driven longterm proliferation of CB cells ( Figure 5C ). Furthermore, MLL-AF9 cells transduced with RUNX1 shRNAs were outcompeted by nontransduced cells during leukemia development in vivo, as indicated by the depletion of venus + cells in leukemic mice (Figure 5D and Supplemental Figure 6A ).
Next, we assessed the effect of a recently reported RUNX1 inhibitor, Ro5-3335, on the growth of MLL-AF9 cells (31) . We confirmed an inhibitory effect of Ro5-3335 on human RUNX1 and RUNX2 using a CB cell culture assay (Supplemental Figure 6 , B and C). We observed that the proliferation of MLL-AF9 cells was more sensitive to Ro5-3335, as compared with the proliferation of CB and K562 cells, correlating with the relative impact of RUNX1 shRNAs on the proliferation of these cells ( Figure 5E ). Ro5-3335 treatment induced cell cycle arrest and apoptosis in MLL-AF9 cells, similar to the effects of shRNA-mediated RUNX1 depletion ( Figure 5 , F and G). We then examined the effect of RUNX1 depletion in primary leukemia cells derived from patients with AML harboring the MLL fusions MLL-SEPT6 and MLL-ENL ( Figure 6A ). The AML cells with MLL-SEPT6 showed good engraftment and myeloid cell expansion in NOD/SCID/IL2rg -/mice expressing human SCF, GMCSF, and IL3 (NSG-S/GM/3: NSGS) (ref. 32 and Figure 6B) . Those AML cells were transduced with NT or RUNX1 shRNAs and were then cultured on a stromal cell line to assist in the in vitro expansion of these primary leukemia cells. As expected, RUNX1 depletion inhibited the growth of the primary AML cells in vitro ( Figure 6 , C and D). We also transplanted the shRNA-transduced patient sample with MLL-SEPT6 directly into the NSGS mice. RUNX1-depleted AML cells showed a reduced engraftment capacity, as indicated by the reduction of the venus + fraction in human myeloid (hCD45 + /hCD33 + ) cells ( Figure 6D ). Thus, RUNX1 supports the maintenance of human MLL fusion leukemia both in vitro and in vivo.
Functional redundancy between RUNX1 and RUNX2 in MLL fusion
leukemia. In addition to RUNX1, there are two other mammalian RUNX transcription factors, RUNX2 and RUNX3, which have redundant functions in murine hematopoiesis (33, 34) . These RUNX proteins had similar effects on human AML cells (Supplemental Figure 7) . Interestingly, the rescue experiment showed that RUNX2, but not RUNX3, restored the efficient growth of RUNX1-depleted human MLL-AF9 cells, suggesting that RUNX2 has the capacity to substitute for RUNX1 in MLL fusion leukemia ( Figure 7A ). Importantly, we recently showed that loss of Runx1 accelerates the development of murine MLL-ENL leukemia using Runx1 knockout mice (11) . The "growth-inhibitory" role of RUNX1 in murine MLL-ENL cells sharply contrasts with the "growth-promoting" role of RUNX1 in human MLL-AF9 cells. This discrepancy probably indicates the compensatory effect of other RUNX proteins in Runx1-deficient murine cells. Indeed, microarray data revealed an Table 5 ). We also found an upregulation of RUNX2 protein in Runx1-deleted murine and human MLL-AF9 cells in vitro ( Figure 7C and Supplemental Figure 8C ). To assess the dosage-dependent function of RUNX in murine leukemia, we established an inducible gene knockout system for Runx1 and its cofactor Cbfb in MLL-AF9 cells ( Figure 7D ). CBFB is an important cofactor for all RUNX proteins, therefore, depletion of CBFB along with RUNX1 will result in a further reduction of RUNX activity.
The deletion of Runx1/Cbfb in MLL-AF9 cells resulted in a substantial reduction of colony numbers, while single deletion of Runx1 showed little effect ( Figure 7E ). Furthermore, Runx1/Cbfb-deleted cells were gradually outcompeted by nonexcised cells, while Runx1deleted MLL-AF9 cells continued to grow even after four rounds of plating ( Figure 7F) .
We also performed similar experiments using a Cre-YFPexpressing retrovirus and bone marrow progenitors derived from mice with wild-type alleles, heterozygous floxed alleles of Runx1/Cbfb (Runx1/Cbfb f/wt ), or homozygous floxed alleles of Cbfb or Runx1/Cbfb (Cbfb f/f or Runx1/Cbfb f/f ) ( Figure 8A) . Again, the combined deletion of Runx1/Cbfb in MLL-AF9 cells caused a marked reduction in colony numbers, whereas Cre expression showed marginal effects in wild-type and Runx1/Cbfb f/wt progenitors expressing MLL-AF9 ( Figure 8B ). Runx1/Cbfb-depleted MLL-AF9 cells lost the characteristic leukemia cell morphology with prominent granules ( Figure 8C ) and contained fewer GR-1/c-KIT double-positive cells than the controls ( Figure 8D ). Single deletion of Cbfb also moderately reduced clonogenic activity and GR-1 expression in MLL-AF9 cells (Figure 8, B and D) . However, the effect of single loss of Cbfb was not as strong as double deletion of Runx1/Cbfb, indicating a CBFB-independent function of RUNX1. The colony-forming activity recovered after three rounds of plating in Runx1/Cbfb-and Cbfb-depleted cultures, however; those colonies contained primarily nonexcised Runx1-and/or Cbfb-floxed alleles (Supplemental Figure 9 ).
Finally, to address whether RUNX1/CBFB are essential to maintain MLL-AF9-induced murine AML in vivo, we used a bone marrow transplant assay (Supplemental Figure 10A ). Mice treated with pIpC to induce Runx1/Cbfb deletion showed less GFP + MLL-AF9 leukemia cells in peripheral blood on day 25 (Supplemental Figure 10B ) and died with significantly longer latencies ( Figure 8E ). In contrast, pIpC sion at 24 hours. Of note, RUNX2, which was upregulated in single Runx1-deleted cells ( Figure 7C ), was downregulated in Runx1/ Cbfb-deleted cells ( Figure 9A ). This was probably due to the loss of CBFB, which protects RUNX proteins from ubiquitin-dependent degradation (35) . The dysregulated genes in Runx1/Cbfb-deleted cells contained several known RUNX1 targets, including RUNX1 itself and C/EBPα (Supplemental Tables 3 and 4 ). Among these candidate Runx target genes, we focused on Bcl2, which was shown to be important for the pathogenesis of MLL fusion leukemia (22, 36) . It was also shown that RUNX1 binds to the TGTGGT sequence in the BCL2 promoter (37) . BCL2 was downregulated not only by Runx1/Cbfb double deletion, but also by single Runx1 deletion in murine MLL-AF9 cells ( Figure 9B ). Additional microarray data using in vivo murine MLL-ENL leu-did not affect the development of leukemia in mice transplanted with control MLL-AF9 cells (Supplemental Figure 10C ). We confirmed the excised allele of Runx1 in GFP + MLL-AF9 cells immediately after pIpC injection, but leukemia cells harvested from moribund mice primarily harbored a nonexcised Runx1 allele ( Figure  8F ). Taken together, these results demonstrate the requirement of a certain level of RUNX activity, even in murine leukemia cells.
BCL2 contributes to the survival effect of RUNX1 in MLL fusion leukemia. To identify downstream RUNX targets, we performed global gene expression analysis in murine Runx1/Cbfb f/f MLL-AF9/CreER cells after treatment with 4OHT or EtOH for 24 hours (Supplemental Figure 11 ). This relatively short-term experiment allowed us to identify early responsive genes upon Runx1/Cbfb depletion. We confirmed the absence of RUNX1 and CBFB protein expres- ( Figure 9G and Supplemental Figure 13A ). BCL2-transduced MLL-AF9 cells were relatively resistant to apoptotic cell death induced by RUNX1 depletion compared with control cells. However, cell cycle arrest induced by RUNX1 depletion became more apparent in BCL2-transduced cells ( Figure 9H and Supplemental Figure 13 , B-D). As a possible explanation for this effect on the cell cycle, we found that CDKN1A was significantly upregulated in RUNX1-depleted human MLL-AF9 cells and Runx1/Cbfb-deleted mouse MLL-AF9 cells. However, CDKN1A knockdown did not rescue the growth defect of RUNX1-depleted human MLL-AF9 cells, suggesting the presence of other factors regulating RUNX1-mediated cell cycle progression (Supplemental Figure 14) . kemia cells also showed substantial downregulation of BCL2 in Runx1-deficient MLL-ENL leukemia cells ( Figure 9C , Supplemental Figure 12 , and Supplemental Table 6 ). In human MLL-AF9 cells, both shRNA-mediated RUNX1 knockdown and Ro5-3333 treatment decreased BCL2 expression at mRNA and protein levels (Figure 9 , D and E). To understand the role for BCL2 in RUNX1mediated cell survival, we first engineered vector or BCL2-overexpressing human MLL-AF9 cells and then assessed the effects of shRNA-mediated RUNX1 depletion in these cells ( Figure 9F ). BCL2-transduced MLL-AF9 cells grew better than vector-transduced cells upon RUNX1 knockdown, although BCL2-transduced cells were not fully rescued from the effects of RUNX1 depletion development of MLL fusion leukemia (45) (46) (47) . Dosage-dependent functions of these genes in myeloid leukemogenesis need to be clarified in future studies.
Mouse models have proven to be invaluable tools for the understanding of human cancer. Nevertheless, significant differences exist between mouse models and clinical diseases. The current study highlights the potential influence on tumor development of a compensatory mechanism in mice lacking individual genes. Our data, together with a recent report showing that RUNX2 is upregulated by MLL-AF9 in mouse bone marrow cells (48) , strongly indicate the functional redundancy between RUNX1 and RUNX2 in MLL fusion leukemia. The upregulated RUNX2 probably provides sufficient RUNX activity for Runx1-deficient murine MLL-ENL cells to develop leukemia. It is not clear why we did not see the compensatory effects in human cell-based models. Given that RUNX1 is not mutated in patients with MLL fusion leukemia, human MLL fusion AML cells may require stronger RUNX activity than the corresponding mouse cells for optimal growth. Alternatively, adverse effects of shRNAs used in human cells and/ or different experimental assays could affect the results. While this manuscript was under review, Wilkinson et al. showed that RUNX1 is a transcriptional target of MLL-AF4 and supports the growth of MLL-AF4 cells (49) . Although they argued that RUNX1 is specifically important for the growth of MLL-AF4 cells, our study clearly demonstrates that other types of MLL fusion leukemia also require a certain level of RUNX activity. Compounds targeting RUNX/ CBFB function will show substantial efficacy in MLL fusion leukemia, and these compounds can be expected to exhibit a reasonable therapeutic window relative to normal blood stem cells.
We identified BCL2 as an important mediator for the survival effect of RUNX1 in human MLL fusion leukemia. However, BCL2 did not rescue the cell cycle arrest induced by RUNX1 depletion. Furthermore, Runx1-deficient murine MLL-AF9 cells still developed leukemia despite reduced BCL2 expression. Therefore, other factors must also contribute to the RUNX1-mediated leukemia cell growth. The mechanisms for RUNX1-mediated cell cycle progression remain elusive, but CDKN1A appears to be at least involved in this process, given its consistent upregulation in RUNX1-inhibited leukemia cells. Further characterization of RUNX/CBFB-mediated gene regulation may reveal the way to specifically block the survival function of RUNX without preventing its tumor suppressor role in promoting myeloid differentiation.
In summary, we found an unexpected survival-and growth-promoting role for RUNX1 in the development and maintenance of AML with leukemogenic fusion proteins. Recent efforts to target this transcription factor complex in CBF leukemia (31) should be extended to AML associated with MLL rearrangements and potentially to other myeloid neoplasms with RUNX1 dysfunction.
Methods
Human cell culture. CD34 + cells were separated using an EasySep CD34 selection kit (STEMCELL Technologies). CB cells and CB cells transduced with leukemia fusion genes were cultured in Iscove's modified Dulbecco's media (IMDM) containing 20% BIT9500 (STEMCELL Technologies) and 10 ng/ml SCF, megakaryocyte growth and development factor (TPO), FLT3 ligand (FLT3L), IL-3, and IL-6, as described previously (15, 16) . Primary AML cells derived from patients were cultured on a stromal cell line, OP9-DL1, with the same culture media.
Vectors and viral transduction. The retroviral constructs pMYs-IRES-EGFP (pMYs-IG), pMYs-RUNX1b-IG, pMYs-RUNX1b/D171N-IG, and pMYs-
Discussion
Primary human cells offer a potentially ideal target for the study of oncogene function. Using human cell-based models, we demonstrated dual functions of RUNX1 in myeloid leukemogenesis. RUNX1 overexpression inhibits the growth of CB cells by inducing myeloid differentiation, whereas a certain level of RUNX1 activity is required for the growth of AML cells. Human AML cells are more sensitive to RUNX1 inhibition probably because their RUNX activity is already reduced. We also used a mouse AML model and showed that the combined loss of RUNX1/CBFB inhibits the development of murine MLL fusion leukemia, while single loss of RUNX1 accelerates it (11) . Based on these results, we propose a model to explain the dosage-dependent function of RUNX in myeloid leukemogenesis ( Figure  10 ). Partial loss of RUNX activity blocks myeloid maturation and supports AML development, while a further reduction of RUNX activity results in cell cycle arrest and cell death.
In the past few decades, the scientific community has primarily focused on "oncogenes" that are overexpressed in tumor cells as ideal therapeutic targets. However, such oncogenes are usually also important for the maintenance of normal stem cells, and therefore it remains unclear whether inhibiting such oncogenes would favor normal cells over tumor cells. Instead, genes that are underexpressed in cancer cells but are essential for their survival will be promising targets to selectively eradicate cancer cells while preserving normal stem cells. Importantly, many so-called "tumor suppressors" appear to have such features. In addition to RUNX1, two other well-known tumor suppressors, PML and FOXOs, were shown to have survival roles in leukemia stem cells (38, 39) . Interestingly, recent genome-wide sequence studies in myeloid neoplasms found inactivating mutations in genes that were shown to have oncogenic properties, including GATA2, EZH2, and NOTCH pathway genes (40) (41) (42) (43) (44) . Although these findings reveal a potential tumor suppressor role for these oncogenes, it is highly likely that these genes still retain some growth-promoting function. Indeed, several recent reports showed an important role for EZH2 in the
Figure 10
Proposed model illustrating dosage-dependent functions of RUNX in myeloid leukemogenesis. Partial inactivation of RUNX activity results in the expansion of myeloid progenitors and the subsequent development of AML. However, a further reduction of RUNX activity caused cell cycle arrest and cell death. AML cells will be more sensitive to RUNX inhibition because RUNX activity is already reduced in them. recipient mouse. The immunodeficient mice were placed on doxycycline chow (TestDiet; Modified Prolab RMH-1500 with 0.0625% doxycycline) prior to, during, and for several weeks after irradiation.
Gene-targeted mice. The mice harboring a Runx1 allele with exon 4 flanked by loxP sites (Runx1 f/f ) (50) and the mice harboring a Cbfb allele with exon 5 flanked by loxP sites (Cbfb f/f ) (51) were crossed to generate Runx1/Cbfb f/f mice. Another Runx1 mutant mouse strain with loxP-flanked exon 5 (52) was used to generate in vivo MLL-ENL leukemia (11) .
Myeloid colony assay. Murine myeloid colony assays were plated in M3434 cytokine-enriched methylcellulose according to the manufacturer's instructions (STEMCELL Technologies). CreER-expressing cells were selected in M3434 containing 1 μg/ml puromycin. Cells (5 × 10 3 ) were plated for each round of plating. Colony counting and replating were performed every 4 or 5 days.
Mouse bone marrow transplantation assay. Bone marrow progenitors (c-KIT + cells) were transduced with MLL-AF9 and were injected into sublethally irradiated (700 Gy) recipient mice via the tail vein. Secondary transplantation was performed in the same way using 1 × 10 6 spleen cells isolated from leukemic mice.
Gene expression analysis. Total RNA was prepared using an RNeasy Mini Kit (QIAGEN). For microarray analysis with MLL-AF9/CreER-expressing Runx1/ Cbfb f/f cells, the quality of the total RNA was checked by an Agilent Bioanalyzer 2100 (Hewlett Packard) using the RNA 6000 Nano Assay. For each sample, the Ambion WT Expression Kit (Life Technologies) synthesized the cDNA target from 300 nanograms of total RNA. Then the GeneChip WT Terminal Labeling Kit (Affymetrix) was used to both chemically fragment and biotin label the cDNA target. Labeled probes were hybridized to the GeneChip Mouse Gene 1.0 ST Array (Affymetrix) and were scanned with the Affymetrix GeneChip Scanner 3000 7G. Raw data files were created by Command Console, the Affymetrix operating software program. All samples were normalized using the robust multichip average (RMA). Upregulated or downregulated genes in Runx1/Cbfb-deleted cells were identified using Qlucore Omics Explorer (http://www.qlucore.com). For microarray analysis with Runx1 f/f -and Runx1 Δ/Δ -MLL-ENL in vivo leukemia cells, labeling of fragmented cDNA was done using the NuGen Ovation Biotin labeling system (NuGEN Technologies). Labeled probes were hybridized to the Mouse Genome 430 2.0 Array (Affymetrix) and scanned with a GeneChip Scanner 3000 7G (Affymetrix). The expression data were extracted from the image files produced with GeneChip 1.0 Operating software (Affymetrix). Normalization and expression value calculations were performed using the DNA Chip Analyzer (www.dchip.org) (53) . Microarray data were deposited in the NCBI's Gene Expression Omnibus (GEO accession numbers GSE47350 and GSE47402).
Statistics. The survival distributions ( Figure 8E ) were compared using a logrank test. A P value of less than 0.05 was considered statistically significant.
Study approval. Human umbilical CB cells and patient samples were obtained from the Translational Trials Development and Support Laboratory at Cincinnati Children's Hospital Medical Center (Cincinnati, Ohio, USA) in accordance with IRB-approved protocols. Written informed consent was obtained in accordance with the Declaration of Helsinki. All mouse experiments were performed under an IACUC-approved protocol of the Cincinnati Children's Hospital in accordance with accepted national standards and guidelines.
